Adult solid tumours

Adult Solid Tumour testing

The Cancer Genetics laboratory at Guy’s Hospital forms part of the South East GLH.

The South East GLH currently provides all Solid Tumour tests aligned to the National Genomic Test Directory (NGTD) utilising two DNA panels and a 103-gene fusion RNA panel. 

We are currently completing validation of a high-throughput, state of the art 500-gene panel, which will be available alongside existing DNA panels. This panel will be implemented in phases between December 2021 and February 2022; it includes additional targets which are likely to be of future prognostic and therapeutic importance. 

If you are a new user of the SE GLH solid tumour service please could you contact us before submitting any samples to discuss the test order process and sample requirements. 

Tests offered

The full list of tests offered can be found in the National Test Directory. This specifies which genomic tests are commissioned by the NHS in England, the technology by which they are available, and the patients who will be eligible to access a test. 

SE GLH: Solid tumour test request forms

We prefer the request form to be completed electronically (PDF with live fields); if hand written, please ensure that all fields are completed and legible.

Please use this Record of Discussion if you are:
  • confirming an identified somatic variant
  • doing predictive testing for known familial variants

Sample type and requirements

The GLH can receive samples in the following formats:

  1. Curls/scrolls
    • If the tumour cellularity of the whole section is >20% curls/scrolls of paraffin sections are acceptable. Please send in a sealed single-use microtube, either 1.5ml or 2ml. Ideally 5 sections of 10micron thickness should be submitted. 
    • Please do not send curls with an overall tumour cellularity of <20%; see section 2.
  1. Slides
    • 5 sections of 10micron thickness on uncharged, unstained glass slides are required. 
    • The slides must be clearly labelled with the sample histology number and patient surname.
    • An H&E section at 4micron should be submitted with the unstained sections – this can be diagnostic H&E or an additional slide cut at the same time as the unstained sections. This slide should be submitted with the USS and the request form. 
    • The area of the tumour must be outlined on the H&E section with a permanent marker pen; this will allow microdissection if necessary. 
    • The marked H&E slide and FFPE unstained slides must have the histology number and patient surname clearly marked on the slides and must correspond to that on the request form. 
    • Sections should be dried prior to transfer to the hub lab.
    • Sections must NOT be baked onto slides. 
    • Please note that spare unstained slides sectioned previously should not be used for molecular analyses. 

All slides or microtubes should be labelled with the laboratory histology number and patient surname. Unstained slides should be air-dried before packaging for dispatch. As RNA integrity from FFPE sections has been observed to decrease over time when exposed to light and air, air-dried sections intended for RNA analysis may benefit from storage in a fridge if not dispatched promptly.

Samples that are referred for MLH1 promoter hypermethlyation as part of the Lynch pathway require a matched normal control sample to run alongside the tumour sample; please send 5ml blood in EDTA. If it is not possible to obtain a blood sample from the patient, please send material from one normal tissue block in addition to the material from the tumour block as either curls or slides as described above.

The sample should be submitted together with the GLH request form fully completed, and a copy of the pathology report if authorised. The transport of the sample and documentation should be via either tracked Royal Mail or other recognised courier services. For more information about sample requirements please view the SEGLH Tissue Management SOP.

Laboratory criteria for rejecting samples

Full patient details must be provided, including full name, date of birth, surgical number of tissue block, along with details of primary tumour type (e.g. non-small cell lung cancer), subtype where applicable (e.g. adenocarcinoma) and simple type (e.g., liver biopsy / EBUS, lymph node).

Tissue blocks are not accepted, any blocks received will be returned untested. 

Factors which affect performance of the test

The tissue must be appropriately fixed in 10% neutral-buffered formalin for no greater than 48h (due to the induction of formalin fixation artefacts). Microtomy of curls/slides must have been performed on microtome configured for molecular use by appropriately trained staff.

Turnaround times

10-14 days

Lab address and opening hours

Cancer Genetics

Genetics Laboratories

5th Floor Tower Wing

Guy’s Hospital

Great Maze Pond




Opening hours: 09:00-17:30



If you would like your results to be discussed at the SE GLH Solid Tumour Genomic Tumour Advisory Board (GTAB) please send a completed referral form along with the results report to

Key contacts

Nicola Foot, Service Lead –

Amy Roe, Operations Lead

Gareth Gerrard, Scientific Lead –


Tel: 020 7188 1716

Policy on personal information protection

To find out more on how we are using personal data to provide genomic testing please visit our privacy page.

GLH complaints policy

For complaints, please visit the Synnovis complaints page for the policy and procedure.

With any Whole Genome Sequencing (WGS) test ordered, a Record of Discussion (RoD) form will also need to be submitted. This document is to record the patient’s consent for genomic testing and their choice on taking part in research. Guidance on the patient choice conversation can be found here
This RoD form will be available for clinicians to download from this webpage. Once completed with the patient, it can be send to the lab with the corresponding test order form and sample.
Tests available to order will be listed in the National Genomic Test Directory. A test order form will soon be made available for clinicians on this webpage to download and complete. This form will include the address of the laboratory that the appropriate sample and completed form needs to be sent to.
Until the new Genomic Laboratory Service goes live, please continue to follow existing test order processes.
Later this year, the online test ordering tool for Whole Genome Sequencing will be integrated into the National Genomics Informatics System (NGIS) and clinicians will be able to search or filter to find a clinical indication, confirm eligibility criteria and start the test request process for their patient.